Why The Next Trillion-Dollar Economy Could Be Built Around Aging
As a plastic surgeon, skincare founder and entrepreneur immersed in the worlds of science and aesthetics, I have a front-row seat to one of the most profound and underappreciated shifts in business today: the rise of the longevity economy. Aging—once associated with decline—is now being rebranded as a premium market opportunity. I believe the next trillion-dollar economy will be built not around youth, but around the pursuit of healthy, optimized aging.
Let's be clear: This is not about vanity. This is about vitality. And forward-thinking business leaders would be wise to take note.
The Demographic Power Shift
The average American now lives to over 77 years. Globally, more than 2 billion people will be over the age of 60 by 2050. According to Morgan Stanley, in the U.S., adults ages 55 and older control about three-quarters of all wealth and 40% of total disposable income. And yet, the cultural obsession with 'youth markets' persists, even as the financial influence of older generations surges.
Meanwhile, Gen X and older Millennials are moving into their 40s and 50s—an age where consumers are not just seeking aesthetic interventions but complete health optimization, from hormone balancing to sleep tracking. These consumers are informed, discerning and willing to invest in products and services that deliver real results. In other words: Aging is not a liability—it is a growth sector.
The Rise Of Longevity As A Lifestyle
Aging is being redefined not as an inevitable loss, but as a lifestyle to be optimized. This is where business opportunities abound, not only in biotech, but also in consumer-facing industries like fitness, nutrition, mental wellness, and, yes, aesthetics.
I've seen explosive interest in:
• Wearable tech that tracks biological age.
• Peptide therapies to increase collagen, boost metabolism and improve sleep.
• Senolytic drugs targeting aging cells at the molecular level.
• Scientific skincare with DNA-repair enzymes, niacinamide, retinoids and barrier-boosting ceramides.
• Precision medicine and hormone panels tailored to each stage of life.
As a plastic surgeon, I see patients not just asking for facelifts or fillers. They ask about NAD, red light therapy, platelet-rich plasma injections and neuroprotective supplements. They want holistic care that preserves how they look and how they feel. The aesthetic industry, once seen as superficial, is evolving into a crucial branch of the broader longevity movement.
The Currency Of Longevity
What's more powerful than financial ROI? Emotional ROI. Aging gracefully taps into one of the deepest human desires: to live fully and beautifully, without losing oneself.
In my practice, I often say that the best surgical and nonsurgical outcomes are the ones that preserve identity while subtly restoring structure. The same applies to business. Companies that help people feel more like themselves—whether that's through better sleep, sharper cognition, improved skin or sustained energy—are more likely to be successful.
This emotional currency transcends industries. It is why brands like Apple invested in health tracking, why LVMH entered the wellness space and why formerly youth-focused beauty giants are pivoting toward 'pro-aging' product lines. They understand that the future is not about looking younger, but about living better.
We can also look at where venture capital is flowing. Altos Labs, backed by Jeff Bezos, is exploring cellular rejuvenation. Bryan Johnson has spent millions self-experimenting to slow aging. Peter Diamandis and Tony Robbins' 'Life Force' movement is bringing precision diagnostics to the masses.
Yet longevity is not just the realm of tech titans. It is also your dermatologist's office. Your gym. Your supplements aisle. Your skincare shelf. Longevity lives in the daily rituals that help people stay resilient—physically, emotionally and socially.
That's why I believe the most exciting innovations won't just come from the lab, but from the intersection of science, service and self-worth. Whether you are a founder, investor or C-suite executive, the question to ask is this: How does your business help people age better?
Why Trust And Results Will Win
Unlike short-term beauty fads, the longevity market demands credibility. Consumers are no longer swayed by vague claims and influencer testimonials. They want data-backed solutions, results they can see and feel and guidance from professionals who understand anatomy, physiology and the interplay between health and appearance.
That's where expertise becomes a differentiator. I believe brands and services led by scientists, physicians and domain experts will rise to the top. Whether you're in skincare, supplements or wellness diagnostics, your ability to earn trust through transparency and evidence is your single most valuable currency.
Businesses looking to enter this space must prioritize education, real clinical outcomes and the long game. You are not selling miracles. You are helping people live better, longer.
Finally, let's not forget the ethical imperative. Businesses must respect the aging consumer—not infantilize them, ignore them or caricature them. This demographic is intelligent, tech-savvy and often more financially empowered than younger consumers. They want to be seen, not sold to. To earn their loyalty, you must offer more than a product. You must offer a promise of respect, results and relevance.
If your business strategy still revolves around youth, you are already behind. The next frontier is not about reversing time, but about owning time—with grace, with integrity and with intention. The most successful companies of the next decade will be those that align with the new definition of aging: not decline, but design. Not desperation, but empowerment. Aging is not the end of growth. I believe it is the beginning of a trillion-dollar revolution.
Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
UPDATE -- HT Vet Survey Reveals HT Vista's Ability to Increase Revenue for Veterinary Clinics
Clinics using the device empower their clinicians with precise cancer risk scoring, driving better outcomes and clinic efficiency HILLSIDE, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- HT Vet, the veterinary health technology company behind HT Vista, the only non-invasive, first-line cancer detection tool for dogs, today announced survey results showing that veterinary practices using the device experienced a 40% increase in mass removal surgeries. The data, collected from ten veterinary practices across the US, UK, and Israel, tracked the number of lumpectomies performed three to six months before and after the introduction of HT Vista. Despite consistent caseloads, all clinics reported an increase in mass removals and biopsies following the device's adoption. Some clinics reported increases as high as 200%, without any corresponding rise in the number of dogs needing lump investigations. This increase in lumpectomies is directly correlated with increased revenue for these clinics. 'I use HT Vista to tell me what to do next,' said Dr. Ohad Barnea, Clinical Director and Co-owner, Tenafly Veterinary Center. 'If I get a high cancer risk result, I recommend diagnostics or removal more urgently, and I will aspirate to check what it is. This helps determine the [surgical] margins I'll need. If it's a low cancer risk result, we might do a minor surgical removal with local anesthesia, preventing benign tumors from becoming problematic. HT Vista provides critical guidance for the next steps, and the clients love the clarity and assurance it gives them.' Outside of the group studied, most clinics reported achieving a positive ROI within four to six months after adopting HT Vista. This is largely due to HT Vista's ability to provide clinicians with a Cancer Risk Score featuring 90% sensitivity and 98% negative predictive value, along with a diagnostic alert when cancer detection specificity exceeds 90%. A 40-second scan with HT Vista's heat diffusion imaging flags masses that require further investigation, eliminating the uncertainty of the 'wait and see' approach. As a result, more dogs receive the diagnostic and surgical care they need. Veterinarians can discuss treatment options with greater confidence, making faster and more informed decisions. 'These results confirm what we've long believed, that giving veterinary teams access to fast, non-invasive cancer screening leads to more confident decision-making and better use of clinic resources,' said Shani Toledano, CEO of HT Vet. 'HT Vista isn't just helping detect potential cancers earlier, it shortens the time between detection and treatment, improving outcomes for dogs, providing peace of mind for their owners, and empowering clinicians to deliver greater value to both patients and the clinic's bottom line.' HT Vet aims to bring HT Vista into every veterinary clinic worldwide. Earlier this year, the company partnered with Patterson Veterinary, one of North America's largest veterinary product distributors, to increase accessibility of HT Vista across the U.S. This partnership, combined with ongoing strategic initiatives, expands access so more veterinary practices worldwide can benefit from HT Vista's proven ability to improve patient outcomes and increase returns. To see detailed survey results, click here. About HT Vet HT Vet is an Israeli-based company aiming to increase early detection of dermal and subcutaneous cancer in dogs. Its revolutionary, patented medical imaging technology, Heat Diffusion Imaging, was developed by a team of experts in the fields of AI, signal analysis, and computer vision, together with top researchers in heat transfer and thermodynamics, oncologists, and radiologists. For more information about the HT Vista device or to schedule a demonstration, please visit HT Vet's website. Media Contact Shahni Ben-HaimSBH Media Relationsshahni@ A photo accompanying this announcement is available at
Yahoo
an hour ago
- Yahoo
A judge blocked a rule to drop medical debt from credit reports. What now?
A recent federal court ruling overturned a Biden-era ban on medical debt in credit reports just as access to healthcare and health insurance is becoming more fragile. The decision could thwart the hopes of an estimated 15 million Americans who might have seen some relief ahead of expected hikes to healthcare premiums, the end of enhanced marketplace subsidies, and an anticipated increase in the number of Americans without insurance. 'We're really concerned that with the loss of insurance altogether, or healthcare becoming more expensive, we're just going to see more medical debt,' said Mona Shah, the senior director of policy and strategy at Community Catalyst, a national nonprofit healthcare advocacy organization. 'With this protection removed around credit reporting, it's going to impact people's overall economic well-being and ability to thrive.' A $49 billion reversal Earlier this month, a federal judge blocked a rule from the Consumer Financial Protection Bureau (CFPB), which had never taken effect, that would have stopped medical bills from appearing on credit reports and barred lenders from using such data to make lending decisions. The CFPB estimated the change could raise impacted consumers' credit scores by an average of 20 points. Healthcare providers typically don't report missed medical bills directly to credit bureaus, according to Equifax, so medical debt often doesn't wind up on a credit report until it's been reported to a collections agency. However, two trade associations successfully argued that the CFPB had overstepped its authority. Under the Trump administration, the CFPB also asked for the rule to be thrown out. In a July 11 ruling, Judge Sean Jordan of the US District Court for the Eastern District of Texas agreed with the trade groups. The ruling comes at an especially precarious time in healthcare. The tax bill signed into law by President Trump this month is expected to leave 10 million Americans without health insurance by 2034, largely due to changes in Medicaid. Meanwhile, enhanced premium tax credits that helped make Affordable Care Act marketplace coverage more affordable will expire at the end of this year after they were not extended in the tax bill, a change that will help contribute to the largest premium increases seen in years in 2026. The end of the subsidies is expected to leave an estimated 4.2 million people uninsured. 'Having more people lose Medicaid and become uninsured, and also lower-income adults losing subsidized marketplace coverage and becoming uninsured, is going to significantly increase medical debt,' said Fredric Blavin, a senior fellow and researcher at the Urban Institute, a Washington-based think tank. Under the Biden administration, the CFPB estimated that removing medical bill information could have wiped $49 billion off the credit reports of about 15 million Americans, noting that medical billing information often contained errors and was a poor predictor of a consumer's creditworthiness. Lower credit scores can damage a person's ability to rent a home, obtain a credit card with a favorable rate, and even impact their job search. In public comments supporting the rule, many Americans shared stories of how medical bills had weighed on their credit, including cancer patients, people who had been in car wrecks, and more. Read more: How are credit scores calculated? Sign up for the Mind Your Money weekly newsletter By subscribing, you are agreeing to Yahoo's Terms and Privacy Policy What should consumers do now? Credit reporting agencies had already voluntarily decided in April 2023 to wipe medical collection debt from consumer credit reports if the balance was below $500. A year earlier, paid medical collection debt was also dropped from credit reports, and consumers were given one year to pay down medical collection debt before it started appearing on their credit reports, rather than six months. Additionally, the CFPB noted that FICO and VantageScore had previously both 'decreased the degree to which medical bills impact a consumer's score.' These combined changes dropped medical debt in collections from most consumers' credit reports, the Urban Institute found, leaving about 4.1% of adults with such data on their records in August 2024, down from 12.6% in February 2022. Additionally, 14 states have provisions in place to remove medical collection debt from credit reports. 'We expect more states to take the same initiative moving forward,' said Breno Braga, a senior fellow and researcher at the Urban Institute. Still, consumers are left with the onerous job of keeping up with these changes and staying on top of their credit as they face mounting bills — along with the resumption of delinquent student loans hitting credit scores. Consumers should regularly check their mail and email for information concerning their credit, while also carefully examining the bills to determine what they owe and what they might be able to contest. When it comes to unaffordable medical care, consumers can ask healthcare providers about financial assistance options. Read more: How to check your credit score for free 'It's really just vigilance and trying to understand what's available in terms of assistance,' said Sarah Chenven, the CEO of Working Credit, a nonprofit organization that helps people build good credit. Consumers should also be cautious about signing up for medical credit cards with a 'deferred interest', said Shah with Community Catalyst, which may subject them to high, retroactive interest charges if they don't pay their bill in a certain promotional period. 'When patients are now faced with these difficult decisions of not being able to pay off these bills right away — worried about how it's going to impact their credit scores, losing their insurance, still needing healthcare — they may be lured into signing up for one of these payment products,' said Shah. Emma Ockerman is a reporter covering the economy and labor for Yahoo Finance. You can reach her at Sign up for the Mind Your Money newsletter Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Trailhead Biosystems® Expands Human Cell-Based Product Line with iPSC-Derived A9 Dopaminergic Neurons
BEACHWOOD, Ohio, July 23, 2025 /CNW/ -- Trailhead Biosystems, Inc. ( a biotechnology company pioneering the creation of induced pluripotent stem cell (iPSC)-derived human cells at scale for drug discovery and cell therapy, introduces TrailBio® A9 Dopaminergic Neurons, a powerful new tool available off-the-shelf for studying Parkinson's disease and other neurodegenerative conditions. A9 dopaminergic neurons play a critical role in movement regulation and are disproportionately affected in Parkinson's disease. Historically, researchers have lacked access to viable human models, relying instead on animal studies with limited relevance. With TrailBio® A9 Dopaminergic Neurons, scientists now have a human-specific platform to investigate disease mechanisms, develop therapies and accelerate drug discovery. "TrailBio® A9 Dopaminergic Neurons open new possibilities for Parkinson's research," said Dr. Jan Jensen, Chief Scientific Officer, Chief Technology Officer and founder of Trailhead Biosystems. "These cells enable researchers to study the vulnerabilities of A9 neurons, helping drive progress toward more effective treatments." "For decades, the lack of human A9 neurons has limited our ability to truly understand Parkinson's disease," added Dr. Nooshin Amini, Scientific Director at Trailhead Biosystems. "Now, with TrailBio® A9 Dopaminergic Neurons, researchers can directly study the exact cells that are most affected, offering hope for groundbreaking insights and future therapies." About Trailhead Biosystems Trailhead Biosystems, Inc. is pioneering an informatics-based approach in regenerative medicine and drug discovery. Founded in 2015 as a spinout from the Cleveland Clinic and Case Western Reserve University, Trailhead emerged from the research of CSO/CTO and founder Dr. Jan Jensen. Trailhead creates optimized human cells at scale with its proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, integrating advanced mathematical modeling with high-throughput robotic manufacturing. This innovative system allows Trailhead to develop specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. TrailBio® A9 Dopaminergic Neurons represent one of many specialized human cell types emerging from this platform, with additional cell models expected in the near future. Learn more about Trailhead Biosystems, TrailBio® A9 Dopaminergic Neurons and HD-DoE® at For more information, please contact: Tim Mauk, Corporate CommunicationsTrailhead BiosystemsEmail: info@ View original content to download multimedia: SOURCE Trailhead Biosystems Inc View original content to download multimedia:
